With the award for up to $27 million from the Advanced Research Projects Agency for Health (ARPA-H), a collaborative research project at the Wyss Institute for Biologically Inspired Engineering at Harvard University will advance a disease-agnostic novel RNA therapeutic with the potential to treat diverse diseases, and to be effectively and rapidly deployable.
AstraZeneca/Daiichi’s ADC shows better survival for nonsquamous NSCLC patients – Pharmaceutical Technology
Datopotamab deruxtecan is comprised of a TROP2-targeting antibody conjugated to a TOP1-inhibitor payload. Image: Getty Images/ wildpixel New data from the TROPION-Lung01 trial show datopotamab
September 10, 2024